FTSE 100 today: Index, pound edge higher; StanChart, Revolution Beauty jump
Thomas Richard Kassberg, the Chief Business Officer and Executive Vice President at Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), a $3.8 billion market cap biotech company currently trading at $41.10, recently sold shares of the company’s common stock, according to a recent SEC filing. According to InvestingPro analysis, the stock is currently trading below its Fair Value. On March 3, Kassberg sold 6,028 shares at a weighted average price of $42.10, totaling approximately $253,778. The shares were sold to cover tax withholdings related to the vesting of restricted stock units (RSUs).
Additionally, on March 1, Kassberg acquired 18,443 shares of common stock at a transaction price of $0, following the conversion of previously granted performance stock units upon certification of performance metrics. After these transactions, Kassberg’s direct ownership stands at 264,730 shares.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that exceeded expectations, driven by strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. Canaccord Genuity responded by raising its price target for Ultragenyx to $136, maintaining a Buy rating. The company’s total revenue for the quarter was $164.9 million, surpassing Goldman Sachs and Visible Alpha Consensus estimates. Ultragenyx has also reiterated its full-year 2025 revenue guidance, projecting between $640 million and $670 million.
Analyst firms have shown varied confidence, with Cantor Fitzgerald maintaining an Overweight rating and a $118 price target, emphasizing the potential of Ultragenyx’s gene therapy programs. H.C. Wainwright reaffirmed a Buy rating with a $95 target, noting the FDA’s acceptance of the Biologics License Application for UX111 for Priority Review. Goldman Sachs also reiterated a Buy rating with a $78 target, highlighting the potential of Ultragenyx’s pipeline, including UX111 for Sanfilippo syndrome.
Ultragenyx’s management has expressed readiness for the potential launch of UX111, aiming for profitability by 2027. The company is also progressing with its DTX301 program for OTC deficiency, with significant developments anticipated in its clinical programs. The outlook from analysts suggests optimism about Ultragenyx’s growth trajectory and future commercial opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.